A highly effective and selective thromboxane synthetase inhibitor, it improves the imbalance between thromboxane A2 (TXA2) and prostaglandin (PGI2) by inhibiting the production of thromboxane A2 (TXA2) and promoting the production of prostacyclin (PGI2), and has the effects of anti-platelet aggregation and vasodilation. It can inhibit cerebral vasospasm, increase cerebral blood flow, improve microcirculation disorders and abnormal energy metabolism in the brain, thereby improving the symptoms of cerebral ischemia in patients after subarachnoid hemorrhage surgery and movement disorders in patients with cerebral thrombosis (acute phase).

This product is a highly effective and selective thromboxane synthetase inhibitor, which improves the imbalance between thromboxane A2 (TXA2) and prostaglandin (PGI2) by inhibiting the production of thromboxane A2 (TXA2) and promoting the production of prostacyclin (PGI2), and has the effects of anti-platelet aggregation and vasodilation. It can inhibit cerebral vasospasm, increase cerebral blood flow, improve microcirculation disorders and abnormal energy metabolism in the brain, thereby improving the symptoms of cerebral ischemia in patients after subarachnoid hemorrhage surgery and movement disorders in patients with cerebral thrombosis (acute phase).

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis. Bacteria have cross-resistance to rifamycin antibiotics. Rifampicin binds firmly to the β-subunit of DNA-dependent RNA polymerase, inhibiting the synthesis of bacterial RNA and preventing the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

It has the effects of promoting normal protein metabolism in the human body, correcting negative nitrogen balance, replenishing protein, and accelerating wound healing.

It has the effects of promoting normal protein metabolism in the human body, correcting negative nitrogen balance, replenishing protein, and accelerating wound healing.